Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 10/20 05:30:07 pm
234.4 CHF   -1.76%
10/20 INOVIO PHARMACE : Begins Phase 1b/2 Cancer Efficacy Trial Combining ..
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 03:56pm CEST

JOHANNESBURG - Aspen yesterday welcomed the Competition Commission's decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commission’s initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts “due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable”.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. “In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany,” the commission said.

“It is, therefore, unlikely that the price charged by Equity could pass the test for excessive pricing.” The commission, however, alleged that Roche and Genentech had engaged in excessive pricing, price discrimination and exclusionary conduct in the provision of breast cancer medicine in South Africa, adding that breast cancer treatment was unaffordable in South Africa.

The commission said investigations on Pfizer for excessive pricing of lung cancer medication in South Africa would continue. The drug maker was the only provider of a lung cancer treatment medication, known asXalkori (crizotinib), in South Africa. The body also alleged that lung cancer treatment in South Africa was unaffordable.

Aspen shares fell 0.01 percent on the JSE yesterday to close at R304.75 a share.

- BUSINESS REPORT

(c) Cape Community 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
10/20 ROCHE : 66-- Notice of Intent-Sole Source IDIQ Roche laboratory supplies
10/20 INOVIO PHARMACEUTICALS : Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T..
10/19 PTC THERAPEUTICS : Spinal Muscular Atrophy Program Advances into Pivotal Study i..
10/19 FOUNDATION MEDICINE : Appoints Tom Civik as Chief Commercial Officer
10/19DJEuropean Corporate Roundup for Thursday
10/19DJEuropean Corporate Roundup for Thursday
10/19 ROCHE : Swiss biotech group Roche sees 5 pct rise in 9-month sales
10/19DJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/19 ROCHE : reports strong sales growth in the first nine months of 2017
10/19 ROCHE : Partitions
More news
News from SeekingAlpha
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 Roche Holding's (RHHBY) CEO Dr. Severin Schwan on Q3 2017 Results - Earnings ..
10/19 Roche Holding ADR (RHHBY) Updates On 3Q17 Sales - Slideshow
Financials ( CHF)
Sales 2017 53 411 M
EBIT 2017 18 409 M
Net income 2017 11 152 M
Debt 2017 9 884 M
Yield 2017 3,67%
P/E ratio 2017 17,46
P/E ratio 2018 15,97
EV / Sales 2017 4,00x
EV / Sales 2018 3,78x
Capitalization 204 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 272  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.0.77%207 116
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501